J. Goldman & Co’s Madrigal Pharmaceuticals MDGL Stock Holding History

J. Goldman & Co’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72M	Buy	+5,069	New	+$2.6M	0.07%	293
2025 Q4	–	Sell	-1,449	Closed	-$665K	–	666
2025 Q3	$665K	Sell	1,449 -2,102	-59%	-$784K	0.02%	362
2025 Q2	$1.07M	Sell	3,551 -6,325	-64%	-$1.88M	0.03%	334
2025 Q1	$3.27M	Buy	+9,876	New	+$3.25M	0.08%	246
2023 Q2	–	Sell	-11,971	Closed	-$3.24M	–	448
2023 Q1	$2.9M	Buy	+11,971	New	+$3.26M	0.12%	190
2018 Q2	–	Sell	-4,528	Closed	-$529K	–	411
2018 Q1	$529K	Buy	+4,528	New	+$559K	0.02%	282
2013 Q3	–	Sell	-2,857	Closed	-$499K	–	291
2013 Q2	$499K	Buy	+2,857	New	+$745K	0.05%	211

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

J. Goldman & Co's MDGL Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 5,069 shares worth $2.72M. The stake represents 0.07% of the portfolio and ranks #293 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in MDGL as recently as Q3 2025.

J. Goldman & Co first reported a position in MDGL in Q2 2013 and has held it in 7 quarters since. The position peaked at $3.27M in Q1 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

J. Goldman & Co held 5,069 shares of Madrigal Pharmaceuticals worth $2.72M as of Q2 2026.
Madrigal Pharmaceuticals was a new J. Goldman & Co position in Q2 2026.
Madrigal Pharmaceuticals made up 0.07% of J. Goldman & Co's portfolio in Q2 2026, its #293 holding.
J. Goldman & Co first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 7 quarters since.
J. Goldman & Co's Madrigal Pharmaceuticals position peaked at $3.27M in Q1 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.